查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1702366

全球免疫測定市場 - 2025-2033

Global Immunoassay Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球免疫測定市場規模達到 368.7 億美元，預計到 2033 年將達到 686 億美元，在 2025-2033 年預測期內的複合年成長率為 7.1%。

免疫測定是一種利用抗原抗體親和力來區分和量化生物樣本中感興趣的分子的生物分析技術。免疫測定是一種能夠快速、準確地識別特定化合物的實驗室程序。

免疫測定廣泛應用於臨床診斷、藥物研發和食品檢測等各個領域，以識別和測量樣本中特定物質的存在。

市場動態：

駕駛員和約束裝置

不斷創新推出先進的免疫分析儀器

免疫測定市場受到多種因素的推動。推動市場發展的重大因素之一包括不斷增加的創新和先進免疫分析儀器的推出。市場的主要參與者正在引入先進的系統，以滿足尋求先進、精確解決方案的專業人士的需求。例如，2023 年 7 月，西門子醫療推出了用於臨床化學和免疫測定測試的 Atellica CI 分析儀。此外，2023年8月，法邦推出了最新的化學發光免疫分析系統Shine i8000/9000。這款高速全自動分析儀在美國臨床化學協會（AACC）臨床實驗室博覽會暨會議上展示，擁有每小時900次測試的超高吞吐量，採用整合緊湊的設計，性能穩定。

同樣在2022年11月，Gethin Biotech在MEDICA推出了新型MAGICAL 6000化學發光免疫分析儀。它是一款緊湊、創新的化學發光免疫分析儀，非常適合需要一步化學發光解決方案的中高工作流程實驗室。

這些公司正在推出具有特定功能的免疫分析系統。例如，2024 年 7 月，HU Group Holdings Inc. 及其全資子公司 Fujirebio 宣布推出適用於全自動、隨機存取 LUMIPULSE G 免疫分析系統的 Lumipulse G GFAP 檢測。僅供研究使用（RUO）的檢測目前已在日本和美國推出。

儀器和試劑成本高

預計儀器和試劑的高成本將對免疫測定市場的成長構成重大挑戰。免疫測定是臨床和研究環境中必不可少的診斷工具，需要專門的、通常昂貴的儀器，以及穩定的檢測試劑供應。這些成本可能過高，特別是對於預算有限的發展中地區的小型實驗室或醫療機構。因此，維護和操作免疫測定系統的財務負擔可能會導致採用率下降，從而阻礙市場成長。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按類型分類的程式碼片段
  • 按產品類型分類的程式碼片段
  • 樣本片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 不斷創新推出先進的免疫分析儀器
      • 慢性病和傳染病發生率上升
    • 限制
      • 儀器和試劑成本高昂
      • 複雜的檢測程序
    • 機會
      • 加強研發
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：免疫分析市場（按類型）

  • 酵素連結免疫吸附試驗
  • 放射免疫分析（RIA）
  • 螢光免疫分析（FIA）
  • 化學發光免疫分析（CLIA）
  • 快速檢測
  • 其他

第6章：免疫分析市場（依產品類型）

  • 試劑和試劑盒
    • ELISA 試劑和試劑盒
    • 快速檢測試劑和試劑盒
    • ELISPOT 試劑與試劑盒
    • 蛋白質印跡試劑和試劑盒
    • 其他
  • 分析器
    • 開放式系統
    • 封閉式系統
  • 軟體與服務

第7章：免疫分析市場（按樣本）

  • 血
  • 唾液
  • 尿
  • 其他

第 8 章：免疫分析市場（按應用）

  • 治療藥物監測
  • 藥物研發
  • 疾病診斷
    • 傳染病
    • 癌症
    • 內分泌學
    • 自體免疫疾病
    • 心臟病學
    • 血液學
    • 其他
  • 其他

第 9 章：免疫分析市場（按最終用戶分類）

  • 醫院
  • 血庫
  • 臨床實驗室
  • 製藥和生物技術公司
  • 學術研究中心
  • 其他

第 10 章：免疫測定市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第12章：公司簡介

  • Beckman Coulter, Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • BioMerieux SA
  • Bio-Rad Laboratories, Inc
  • Abbott
  • DiaSorin SpA
  • BD
  • Thermo Fisher Scientific Inc.
  • Merck KGaA

第13章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 14 章：附錄

簡介目錄
Product Code: CD1273

The global immunoassay market reached US$ 36.87 billion in 2024 and is expected to reach US$ 68.60 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

Immunoassay is a bioanalytical technique that utilizes antigen-antibody affinity to differentiate and quantify molecules of interest in biological samples. Immunoassays are laboratory procedures that enable the rapid and precise identification of specific compounds.

Immunoassays are widely used in various fields, including clinical diagnostics, drug discovery, and food testing, to identify and measure the presence of specific substances in a sample.

Market Dynamics: Drivers & Restraints

Increasing Innovation and Launches of Advanced Immunoassay Instruments

The immunoassay market is driven by several factors. One of the significant factors driving the market include increasing innovation and launches of advanced immunoassay instruments. Key players in the market are introducing advanced systems to meet the needs of professionals seeking solutions that are advanced and precise. For instance, in July 2023, Siemens Healthineers introduced the Atellica CI Analyzer for clinical chemistry and immunoassay testing. Also, in August 2023, Fapon launched its latest chemiluminescence immunoassay system, Shine i8000/9000. The high-speed and fully automated analyzer has an ultra-high throughput of 900 tests per hour and features an integrated and compact design with stable performance at the American Association of Clinical Chemistry (AACC) Clinical Lab Expo and Meeting.

Similarly in November 2022, Gethin Biotech launched the new MAGICAL 6000 chemiluminescence immunoassay Analyzer at MEDICA. It is a compact and innovative chemiluminescence immunoassay analyzer that is ideal for mid to high-workflow laboratories that require a one-step chemiluminescence solution.

The companies are introducing immunoassay systems with specific features. For instance, in July 2024, H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE G immunoassay systems. The Research Use Only (RUO) assay is now available in Japan and the United States.

High Cost of Instruments & Reagents

The high cost of instruments and reagents is anticipated to pose a significant challenge to the growth of the immunoassay market. Immunoassays, which are essential diagnostic tools in clinical and research settings, require specialized and often expensive instruments, as well as a consistent supply of reagents for testing. These costs can be prohibitive, especially for smaller laboratories or healthcare facilities in developing regions with limited budgets. As a result, the financial burden of maintaining and operating immunoassay systems could lead to a slower adoption rate, hindering market growth.

Segment Analysis

The global immunoassay market is segmented based on type, product type, specimen, application, end-user, and region.

Type:

ELISA in the type segment is expected to dominate the immunoassay market.

The ELISA segment is expected to hold the major market share over the forecast period. ELISA is an immunological assay commonly used to measure antibodies, antigens, proteins, and glycoproteins in biological samples. Some examples include diagnosis of HIV infection, pregnancy tests, and measurement of cytokines or soluble receptors in cell supernatant or serum.

The ELISA technique is most frequently used due to its ability and efficiency in detecting and quantifying biomarkers. A wide range of conditions, from bacterial and viral infections (like Lyme disease and HIV) to endocrine conditions, like thyroid disease can be detected using ELISA which makes it more preferable over other immunoassays. Several existing and emerging market players are adopting strategies such as partnerships and collaborations with each other to expand their businesses which is contributing to the segment's expansion.

Many key players are launching efficient and advanced ELISA kits that help in detecting disease conditions. For instance, in February 2023, Charles River Laboratories International, Inc. announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics.

Additionally, in February 2024, Krishgen Biosystems is proud to announce the launch of our newest product, the CRM197 ELISA. This kit is designed with a direct sandwich assay format to facilitate accurate and efficient detection of CRM197 with better specificity and sensitivity compared to conventional ELISA kits which employ only one antibody. Double antibodies are used in this kit.CRM197 ELISA kit is used as an analytical tool for the quantitative determination of CRM197 in culture supernatants, vaccines and other biological preparations.

Geographical Analysis

North America is expected to dominate the immunoassay market.

North America holds the largest market share and is expected to continue throughout the forecast period. The rise in demand for diagnostics related to chronic diseases and the availability of technologically advanced diagnostic techniques are expected to propel market growth over the forecast period.

The rising prevalence of infectious diseases and other diseases such as cardiovascular diseases, and cancer among others is creating an opportunity for local market players to boost their sales of diagnostic products. The incidence of diseases such as diabetes, cancer, and infectious diseases increases the demand for diagnostic tests, especially immunoassays, for early detection and observation. Collaborations among academic institutions, research groups, and companies allow for the exchange of knowledge and resources, which boosts market innovation.

The key market players are introducing innovative solutions with advanced features which could increase the region's market expansion. For instance, in July 2024, Beckman Coulter Diagnostics launched the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer. Utilizing Beckman Coulter's common reagents and consumables across its scalable clinical chemistry and immunoassay portfolio, the DxC 500i Analyzer enables commutable patient results, offering hospitals and healthcare networks strategic benefits in patient care and inventory management. Additionally, the increasing research and development and the increasing drug discovery in the region are also expected to propel the market growth.

Competitive Landscape

The global market players in the immunoassay market include Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, BioMerieux SA, Bio-Rad Laboratories, Inc., Abbott, DiaSorin S.p.A., BD, Thermo Fisher Scientific Inc., and Merck KGaA, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global immunoassay market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Product Type
  • 2.5. Snippet by Specimen
  • 2.6. Snippet by Application
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Innovation and Launches of Advanced Immunoassay Instruments
      • 3.1.1.2. Rising Prevalence of Chronic & Infectious Diseases
    • 3.1.2. Restraints
      • 3.1.2.1. The High Cost of Instruments & Reagents
      • 3.1.2.2. Complex Assay Procedures
    • 3.1.3. Opportunity
      • 3.1.3.1. Increasing Research and Development
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Immunoassay Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. ELISA*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Radioimmunoassay (RIA)
  • 5.4. Fluorescence Immunoassays (FIA)
  • 5.5. Chemiluminescence Immunoassays (CLIA)
  • 5.6. Rapid Assays
  • 5.7. Others

6. Immunoassay Market, By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Reagents & kits*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. ELISA Reagents & Kits
    • 6.2.4. Rapid Test Reagents & Kits
    • 6.2.5. ELISPOT Reagents & Kits
    • 6.2.6. Western Blot Reagents & Kits
    • 6.2.7. Others
  • 6.3. Analyzers
    • 6.3.1. Open-ended Systems
    • 6.3.2. Closed-ended Systems
  • 6.4. Software & Services

7. Immunoassay Market, By Specimen

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
    • 7.1.2. Market Attractiveness Index, By Specimen
  • 7.2. Blood*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Saliva
  • 7.4. Urine
  • 7.5. Other

8. Immunoassay Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Therapeutic Drug Monitoring*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Drug Discovery
  • 8.4. Disease Diagnosis
    • 8.4.1. Infectious Disease
    • 8.4.2. Cancer
    • 8.4.3. Endocrinology
    • 8.4.4. Autoimmune Disorders
    • 8.4.5. Cardiology
    • 8.4.6. Hematology
    • 8.4.7. Others
  • 8.5. Other

9. Immunoassay Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Blood Banks
  • 9.4. Clinical Laboratories
  • 9.5. Pharmaceutical and Biotech Companies
  • 9.6. Academic Research Centers
  • 9.7. Others

10. Immunoassay Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Beckman Coulter, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals, etc.
    • 12.1.5. SWOT Analysis
  • 12.2. F. Hoffmann-La Roche Ltd
  • 12.3. Siemens Healthineers AG
  • 12.4. BioMerieux SA
  • 12.5. Bio-Rad Laboratories, Inc
  • 12.6. Abbott
  • 12.7. DiaSorin S.p.A.
  • 12.8. BD
  • 12.9. Thermo Fisher Scientific Inc.
  • 12.10. Merck KGaA

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us